The aporphine alkaloid boldine induces adiponectin expression and regulation in 3T3-L1 cells

Journal of Medicinal Food

Volumn 12, Issue 5, 2009, Pages 1074-1083

  Yu, Bangning ^a   Cook, Carla ^b   Santanam, Nalini ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipogenesis; Antioxidant; Oxidative stress; Peroxisome proliferator activated receptors

Indexed keywords

ADIPONECTIN; BOLDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; HYDROGEN PEROXIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ANIMALS; ANTIOXIDANTS; APORPHINES; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HYDROGEN PEROXIDE; MICE; PEUMUS; PLANT BARK; PLANT EXTRACTS; PLANT LEAVES; POLYMERASE CHAIN REACTION; PPAR GAMMA; RESPONSE ELEMENTS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

PEUMUS BOLDUS;

EID: 70350519601     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2008.0230     Document Type: Article

References (67)

1. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 1996;271: 10697-10703.
2. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
3. Swarbrick MM, Havel PJ: Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008;6:87-102.
4. Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007;18: 263-270.
5. Sheng T, Yang K: Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35:321-326.
6. Tarquini R, Lazzeri C, Laffi G, Gensini GF: Adiponectin and the cardiovascular system: From risk to disease. Intern Emerg Med 2007;2:165-176.
7. Stern N, Osher E, Greenman Y: Hypoadiponectinemia as a marker of adipocyte dysfunction-Part I: The biology of adiponectin. J Cardiometab Syndr 2007;2:174-182.
8. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS: Adiponectin: A biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008;15:565-576.
9. Giannessi D, Maltinti M, Del Ry S: Adiponectin circulating levels: A new emerging biomarker of cardiovascular risk. Pharmacol Res 2007;56:459-467.
10. Mao X, Hong JY, Dong LQ: The adiponectin signaling pathway as a novel pharmacological target. Mini Rev Med Chem 2006;6:1331-1340.
11. Brun RP, Kim JB, Hu E, Altiok S, Spiegelman BM: Adipocyte differentiation: A transcriptional regulatory cascade. Curr Opin Cell Biol 1996;8:826-832.
12. Farmer SR: Regulation of PPARgamma activity during adipogenesis. Int J Obes (Lond) 2005;29(Suppl 1):S13-S16.
13. Sharma AM, Staels B: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-395.
14. Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE, Shao J: C=EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 2005;54:1744-1754.
15. Kita A, Yamasaki H, Kuwahara H, Moriuchi A, Fukushima K, Kobayashi M, Fukushima T, Takahashi R, Abiru N, Uotani S, Kawasaki E, Eguchi K: Identification of the promoter region required for human adiponectin gene transcription: Association with CCAAT=enhancer binding protein-beta and tumor necrosis factor- alpha. Biochem Biophys Res Commun 2005;331:484-490.
16. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T: Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007;27:635-641.
17. Mineo H, Oda C, Chiji H, Kawada T, Shimizu K, Taira T: Thiazolidinediones exhibit different effects on preadipocytes isolated from rat mesenteric fat tissue and cell line 3T3-L1 cells derived from mice. Cell Biol Int 2007;31:703-710.
18. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-12162.
19. Moller DE, Berger JP: Role of PPARs in the regulation of obesity- related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003;27(Suppl 3):S17-S21.
20. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
21. Ferroni P, Basili S, Falco A, Davi G: Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424-431.
22. Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24-30.
23. Takemura Y, Walsh K, Ouchi N: Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007;9:238-243.
24. Fantuzzi G: Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008;121:326-330.
25. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K: Angiotensin- II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005;48:1066-1074.
26. Soares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Bouzaidi-Tiali N, Lagarde M, Geloen A: Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38:882-889.
27. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F, Ma XL: Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative=nitrative stress and differential regulation of eNOS= iNOS activity. Am J Physiol Endocrinol Metab 2007;293:E1703-E1708.
28. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL: Adiponectin cardioprotection after myocardial ischemia=reperfusion involves the reduction of oxidative=nitrative stress. Circulation 2007;115: 1408-1416.
29. Shimada M, Mochizuki K, Sakurai N, Goda T: Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem 2007;71:2079-2082.
30. Cho SY, Park PJ, Shin HJ, Kim YK, Shin DW, Shin ES, Lee HH, Lee BG, Baik JH, Lee TR: (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2007;292:E1166-E1172.
31. Schmeda-Hirschmann G, Rodriguez JA, Theoduloz C, Astudillo SL, Feresin GE, Tapia A: Free-radical scavengers and antioxidants from Peumus boldus Mol. (''Boldo''). Free Radic Res 2003;37:447-452.
32. Speisky H, Cassels BK: Boldo and boldine: An emerging case of natural drug development. Pharmacol Res 1994;29:1-12.
33. O'Brien P, Carrasco-Pozo C, Speisky H: Boldine and its antioxidant or health-promoting properties. Chem Biol Interact 2006;159:1-17.
34. Speisky H, Cassels BK, Lissi EA, Videla LA: Antioxidant properties of the alkaloid boldine in systems undergoing lipid peroxidation and enzyme inactivation. Biochem Pharmacol 1991;41:1575-1581.
35. Kringstein P, Cederbaum AI: Boldine prevents human liver microsomal lipid peroxidation and inactivation of cytochrome P4502E1. Free Radic Biol Med 1995;18:559-563.
36. Milian L, Estelles R, Abarca B, Ballesteros R, Sanz MJ, Blazquez MA: Reactive oxygen species (ROS) generation inhibited by aporphine and phenanthrene alkaloids semi-synthesized from natural boldine. Chem Pharm Bull (Tokyo) 2004;52:696-699.
37. Jimenez I, Lissi EA, Speisky H: Free-radical-induced inactivation of lysozyme and carbonyl residue generation in protein are not necessarily associated. Arch Biochem Biophys 2000;381: 247-252.
38. Kubinova R, Machala M, Minksova K, Neca J, Suchy V: Chemoprotective activity of boldine: modulation of drug-metabolizing enzymes. Pharmazie 2001;56:242-243.
39. Jimenez I, Garrido A, Bannach R, Gotteland M, Speisky H: Protective effects of boldine against free radical-induced erythrocyte lysis. Phytother Res 2000;14:339-343.
40. Ubeda A, Montesinos C, Paya M, Alcaraz MJ: Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic Biol Med 1993;15:159-167.
41. Backhouse N, Delporte C, Givernau M, Cassels BK, Valenzuela A, Speisky H: Anti-inflammatory and antipyretic effects of boldine. Agents Actions 1994;42:114-117.
42. Lanhers MC, Joyeux M, Soulimani R, Fleurentin J, Sayag M, Mortier F, Younos C, Pelt JM: Hepatoprotective and antiinflammatory effects of a traditional medicinal plant of Chile, Peumus boldus. Planta Med 1991;57:110-115.
43. Jang YY, Song JH, Shin YK, Han ES, Lee CS: Protective effect of boldine on oxidative mitochondrial damage in streptozotocininduced diabetic rats. Pharmacol Res 2000;42:361-371.
44. Chi TC, Lee SS, Su MJ: Antihyperglycemic effect of aporphines and their derivatives in normal and diabetic rats. Planta Med 2006;72:1175-1180.
45. Santanam N, Penumetcha M, Speisky H, Parthasarathy S: A novel alkaloid antioxidant, Boldine and synthetic antioxidant, reduced form of RU486, inhibit the oxidation of LDL in-vitro and atherosclerosis in vivo in LDLR-=- mice. Atherosclerosis 2004;173:203-210.
46. Fox KE, Fankell DM, Erickson PF, Majka SM, Crossno JT Jr, KlemmDJ: Depletion of cAMP-response element-binding protein= ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT=enhancer-binding protein (C=EBP) alpha, C= EBP beta, or PPARgamma 2.JBiolChem2006;281:40341-40353.
47. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
48. James WP: The epidemiology of obesity: The size of the problem. J Intern Med 2008;263:336-352.
49. Pradhan A: Obesity, metabolic syndrome, and type 2 diabetes: Inflammatory basis of glucose metabolic disorders. Nutr Rev 2007;65:S152-S156.
50. Lane G: Obesity and gynaecological cancer. Menopause Int 2008;14:33-37.
51. Hsu CL, Yen GC: Effects of flavonoids and phenolic acids on the inhibition of adipogenesis in 3T3-L1 adipocytes. J Agric Food Chem 2007;55:8404-8410.
52. Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS: Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways. J Biol Chem 2003;278:34823-34833.
53. Pinent M, Blade MC, Salvado MJ, Arola L, Hackl H, Quackenbush J, Trajanoski Z, Ardevol A: Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation. Int J Obes (Lond) 2005;29:934-941.
54. Lin J, Della-Fera MA, Baile CA: Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res 2005;13:982-990.
55. Rayalam S, Della-Fera MA, Yang JY, Park HJ, Ambati S, Baile CA: Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes.JNutr 2007;137:2668-2673.
56. Salma N, Xiao H, Imbalzano AN: Temporal recruitment of CCAAT=enhancer-binding proteins to early and late adipogenic promoters in vivo. J Mol Endocrinol 2006;36:139-151.
57. Steffes MW, Gross MD, Lee DH, Schreiner PJ, Jacobs DR Jr: Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: The Coronary Artery Risk Development in Young Adults Study. Obesity (Silver Spring) 2006;14:319-326.
58. Iwata C, Wang X, Uchida K, Nakanishi N, Hattori Y: Buthionine sulfoximine causes endothelium dependent hyper-relaxation and hypoadiponectinemia. Life Sci 2007;80:873-878.
59. Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, Ishimaru S, Ohtsuka Y, Nishimura M: Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006;339:624-632.
60. Magalang UJ, Rajappan R, Hunter MG, Kutala VK, Kuppusamy P, Wewers MD, Marsh CB, Parinandi NL: Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006;8:2179-2186.
61. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R, Goldstein BJ: Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: Evidence for involvement of a cAMP signaling pathway. Diabetes 2006;55:1840-1846.
62. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A: Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006;341:549-556.
63. Gong H, Ni Y, Guo X, Fei L, Pan X, Guo M, Chen R: Resistin promotes 3T3-L1 preadipocyte differentiation. Eur J Endocrinol 2004;150:885-892.
64. Stevigny C, Bailly C, Quetin-Leclercq J: Cytotoxic and antitumor potentialities of aporphinoid alkaloids. Curr Med Chem Anticancer Agents 2005;5:173-182.
65. Konrath EL, Santin K, Nassif M, Latini A, Henriques A, Salbego C: Antioxidant and pro-oxidant properties of boldine on hippocampal slices exposed to oxygen-glucose deprivation in vitro. Neurotoxicology 2008;29:1136-1140.
66. Parthasarathy S, Khan-Merchant N, Penumetcha M, Khan BV, Santanam N: Did the antioxidant trials fail to validate the oxidation hypothesis? Curr Atheroscler Rep 2001;3:392-398.
67. Traber MG, Frei B, Beckman JS: Vitamin E revisited: Do new data validate benefits for chronic disease prevention? Curr Opin Lipidol 2008;19:30-38.